Combinatorial Analgesic and Virtual Reality Therapy for Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, particularly for chronic pain, often rely on opioids that have limited effectiveness, high side effects, and risk of addiction, failing to address both physiological and psychological components of pain.
Innovation Solution
A combinatorial therapeutic system combining centrally and peripherally acting analgesics like oliceridine and bupivacaine-meloxicam with artificial sensory experiences such as virtual reality neuropsychological therapy (VRNT) to provide systemic exposure and psychological intervention for pain management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid analgesics are used for pain management, then pain relief is achieved, but side effects and addiction risk increase
Solution Approach 1:
The patent combines multiple analgesic mechanisms (centrally acting opioid receptor agonist oliceridine with peripherally acting NSAID bupivacaine-meloxicam) into a single fixed-dose combination product. This merging allows synergistic pain relief while enabling lower doses of each individual agent, thereby reducing side effects and addiction risk associated with high-dose opioids alone.
Solution Approach 2:
The patent changes the dosing parameters by providing a fixed-dose combination that delivers precise, controlled amounts of each active ingredient. This parameter control ensures optimal therapeutic effect while minimizing excessive dosing that leads to side effects and addiction, representing a shift from variable to controlled dosing parameters.
2Reliability
If high doses of analgesics are administered, then pain relief effectiveness improves, but frequency of administration and dosage requirements increase
Solution Approach 1:
By merging two analgesics with different mechanisms of action into one combination product, the patent achieves enhanced pain relief effectiveness that allows reduction in the quantity of each individual substance required. The synergistic effect means lower doses of both oliceridine and bupivacaine-meloxicam can be used together compared to using high doses of either agent alone.
3Reliability
If conventional analgesics are used, then pain masking is achieved, but underlying psychological components are not addressed
Solution Approach 1:
The patent creates a multi-functional therapeutic approach where the combination product addresses both physiological pain pathways (through dual mechanism of action on central and peripheral systems) and can be integrated with psychological therapies. This universality allows the treatment to tackle multiple components of chronic pain simultaneously rather than just masking symptoms.
Data Source
AI summary
Combinatorial therapeutic systems can include a systemic, centrally and peripherally acting analgesics and an artificial sensory experience. Methods for treating and/or mitigating pain can include receiving a systemic, centrally and peripherally acting analgesic and an artificial sensory experience. The analgesic can include oliceridine or bupivacaine-meloxicam. The artificial sensory experience can include one or more of 2D/3D/4D artificial sensory experiences, holography, augmented reality, virtual reality, and/or mixed reality. In some instances, the virtual reality is virtual reality neuropsychological therapy or virtual reality distraction therapy.